Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1032-1037
Published online before print February 24, 2005, doi: 10.1161/01.ATV.0000160342.20342.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/5/1032    most recent
01.ATV.0000160342.20342.00v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falcone, C.
Right arrow Articles by Geroldi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Falcone, C.
Right arrow Articles by Geroldi, D.
Related Collections
Right arrow Chronic ischemic heart disease
Right arrow Risk Factors
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1032.)
© 2005 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men

Colomba Falcone; Enzo Emanuele; Angela D’Angelo; Maria P. Buzzi; Chiara Belvito; Mariaclara Cuccia; Diego Geroldi

From the Department of Cardiology (C.F., M.P.B., C.B.), the Molecular Medicine Laboratory (E.E.), the Department of Internal Medicine and Medical Therapeutics (A.D., D.G.), University Hospital IRCCS San Matteo, Italy; and the Department of Genetics and Microbiology (M.C.), University of Pavia, Pavia, Italy.

Correspondence to Colomba Falcone, MD, Department of Cardiology, University Hospital IRCCS San Matteo, University of Pavia, Piazzale Golgi 2, 27100, Pavia, Italy. E-mail c.falcone{at}smatteo.pv.it

Objective— The receptor for advanced glycation end products (RAGE) is a cell surface receptor whose signaling pathway has been implicated in atherogenesis. RAGE has an endogenous secretory receptor form, called soluble RAGE (sRAGE), that could exert antiatherogenic effects by acting as a decoy. We sought to determine whether a decreased plasma level of sRAGE could be independently associated with the prevalence of coronary artery disease (CAD) in nondiabetic men.

Methods and Results— Plasma levels of sRAGE were determined in 328 nondiabetic male patients with angiographically proved CAD and in 328 age-matched healthy controls. The concentration of sRAGE in plasma was significantly lower (P<0.0001) in CAD cases [median (interquartile range): 966 (658–1372) pg/mL] than in control subjects [1335 (936–1954) pg/mL]. In logistic regression analysis, the multivariate-adjusted odds ratio for the presence of CAD was 6.719 (95% confidence interval, 3.773 to 11.964; P<0.0001) when the lowest quartile of the sRAGE level was compared with the highest quartile.

Conclusions— Our findings indicate that low levels of sRAGE in plasma are independently associated with the presence of CAD in nondiabetic men and suggest that sRAGE is one of the clinically important molecules associated with atherosclerosis.

Soluble RAGE could prevent the adverse effects of RAGE signaling by acting as a decoy. We found that low levels of sRAGE in plasma are independently associated with the presence of CAD in nondiabetic men. These findings suggest that sRAGE is one of the clinically important molecules associated with atherosclerosis.


Key Words: coronary artery disease • risk factor • soluble receptor for advanced glycation end products


Related Article:

Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease: The Next C-Reactive Protein?
Barry I. Hudson, Evis Harja, Bernhard Moser, and Ann Marie Schmidt
Arterioscler. Thromb. Vasc. Biol. 2005 25: 879-882. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
H. L. Nienhuis, K. de Leeuw, J. Bijzet, A. Smit, C. G. Schalkwijk, R. Graaff, C. G. Kallenberg, and M. Bijl
Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts
Rheumatology, August 13, 2008; (2008) ken302v1.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Montaner, M. Perea-Gainza, P. Delgado, M. Ribo, P. Chacon, A. Rosell, M. Quintana, M. E. Palacios, C. A. Molina, and J. Alvarez-Sabin
Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers
Stroke, August 1, 2008; 39(8): 2280 - 2287.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
Z Sternberg, B Weinstock-Guttman, D Hojnacki, P Zamboni, R Zivadinov, K Chadha, A Lieberman, L Kazim, A Drake, P Rocco, et al.
Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity
Multiple Sclerosis, July 1, 2008; 14(6): 759 - 763.
[Abstract] [PDF]


Home page
FASEB J.Home page
B. I. Hudson, A. M. Carter, E. Harja, A. Z. Kalea, M. Arriero, H. Yang, P. J. Grant, and A. M. Schmidt
Identification, classification, and expression of RAGE gene splice variants
FASEB J, May 1, 2008; 22(5): 1572 - 1580.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Kalousova, M. Jachymova, O. Mestek, M. Hodkova, M. Kazderova, V. Tesar, and T. Zima
Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients
Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2020 - 2026.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Koyama, T. Shoji, S. Fukumoto, K. Shinohara, T. Shoji, M. Emoto, K. Mori, H. Tahara, E. Ishimura, R. Kakiya, et al.
Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 147 - 153.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Basta, A. M. Sironi, G. Lazzerini, S. Del Turco, E. Buzzigoli, A. Casolaro, A. Natali, E. Ferrannini, and A. Gastaldelli
Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4628 - 4634.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T. Shoji, H. Koyama, T. Morioka, S. Tanaka, A. Kizu, K. Motoyama, K. Mori, S. Fukumoto, A. Shioi, N. Shimogaito, et al.
Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes.
Diabetes, August 1, 2006; 55(8): 2245 - 2255.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Koyama, T. Shoji, H. Yokoyama, K. Motoyama, K. Mori, S. Fukumoto, M. Emoto, T. Shoji, H. Tamei, H. Matsuki, et al.
Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2587 - 2593.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
E. Emanuele, A. D'Angelo, C. Tomaino, G. Binetti, R. Ghidoni, P. Politi, L. Bernardi, R. Maletta, A. C. Bruni, and D. Geroldi
Circulating Levels of Soluble Receptor for Advanced Glycation End Products in Alzheimer Disease and Vascular Dementia
Arch Neurol, November 1, 2005; 62(11): 1734 - 1736.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. I. Hudson, E. Harja, B. Moser, and A. M. Schmidt
Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease: The Next C-Reactive Protein?
Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 879 - 882.
[Full Text] [PDF]